Journal Watch · Nature Biotechnology · 2026
Single-cell polygenic risk scores dissect cellular and molecular heterogeneity of complex human diseases.
Applied to these diseases, scPRS fine-maps causal cell types and cell-type-specific variants and genes, demonstrating its ability to bridge genetic risk with cell-specific biology. scPRS provides a unified framework for genetic risk prediction and mechanistic dissection of complex diseases, laying a methodological foundation for single-cell genetics.
TL;DR
Applied to these diseases, scPRS fine-maps causal cell types and cell-type-specific variants and genes, demonstrating its ability to bridge genetic risk with cell-specific biology. scPRS provides a unified framework for genetic risk prediction and mechanistic dissection of complex diseases, laying a methodological foundation for single-cell genetics.
Key findings
- Beyond risk prediction, scPRS prioritizes disease-critical cells and, when combined with a layered multiomic analysis, links risk variants to gene regulation in a cell-type-specific manner.
- Applied to these diseases, scPRS fine-maps causal cell types and cell-type-specific variants and genes, demonstrating its ability to bridge genetic risk with cell-specific biology. scPRS provides a unified framework for genetic risk prediction and mechanistic dissection of complex diseases, laying a methodological foundation for single-cell genetics.
What they did
We introduce scPRS, a graph neural network-based framework that computes single-cell-resolved PRSs by integrating reference single-cell chromatin accessibility profiles. scPRS outperforms traditional PRS approaches in genetic risk prediction, as demonstrated across multiple diseases including type 2 diabetes, hypertrophic cardiomyopathy, Alzheimer disease and severe COVID-19.
Full abstract (original)
Background: Polygenic risk scores (PRSs) predict an individual's genetic risk for complex diseases, yet their utility in elucidating disease biology remains limited.
What they did: We introduce scPRS, a graph neural network-based framework that computes single-cell-resolved PRSs by integrating reference single-cell chromatin accessibility profiles. scPRS outperforms traditional PRS approaches in genetic risk prediction, as demonstrated across multiple diseases including type 2 diabetes, hypertrophic cardiomyopathy, Alzheimer disease and severe COVID-19.
Results & conclusions: Beyond risk prediction, scPRS prioritizes disease-critical cells and, when combined with a layered multiomic analysis, links risk variants to gene regulation in a cell-type-specific manner. Applied to these diseases, scPRS fine-maps causal cell types and cell-type-specific variants and genes, demonstrating its ability to bridge genetic risk with cell-specific biology. scPRS provides a unified framework for genetic risk prediction and mechanistic dissection of complex diseases, laying a methodological foundation for single-cell genetics.
Abstract © the authors / Nature Biotechnology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1038/s41587-025-02725-6 · PubMed 40715455.
Why it matters for pharma & biotech
- Relevant to Biology & Life Sciences teams tracking Nature Biotechnology for new targets, mechanisms and biomarkers.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Nature Biotechnology study find?
Applied to these diseases, scPRS fine-maps causal cell types and cell-type-specific variants and genes, demonstrating its ability to bridge genetic risk with cell-specific biology. scPRS provides a unified framework for genetic risk prediction and mechanistic dissection of complex diseases, laying a methodological foundation for single-cell genetics.
What type of study is this?
It is a genomics / omics study, published in Nature Biotechnology in 2026. We introduce scPRS, a graph neural network-based framework that computes single-cell-resolved PRSs by integrating reference single-cell chromatin accessibility profiles.
Where can I read the original paper?
The original is at the publisher via DOI 10.1038/s41587-025-02725-6. PubMed ID: 40715455. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/single-cell-polygenic-risk-scores-dissect-cellular-and-molecular-heterog-027256/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides